Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands			3 Months Ended			9 Months Ended
	Jul. 11, 2022 USD ($)	Feb. 17, 2022 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($) Director	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Total debt			$ 453,500			$ 453,500		$ 549,704
Remeasurement loss					$ 7,800
Net loss attributable to Innoviva stockholders			82,046	$ 265,523		118,191	$ 282,235
Net income (loss) attributable to noncontrolling interests			$ 0	(36,176)		$ 0	6,341
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of investee's board members which may be designated by the Company | Director						2
Payment towards convertible promissory note	$ 0
Net loss attributable to Innoviva stockholders				$ 2,700			$ 13,600
Measurement period adjustments for change in value of goodwill						$ 1,200
Measurement period adjustments for change in value of intangible assets						800
Noncontrolling interest		$ 38,500
Measurement period adjustments for change in value of deferred tax liabilities						$ 400
Entasis Therapeutics Holdings Inc | Consolidated Investees [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity method investment ownership percentage		59.90%
Entasis Therapeutics Holdings Inc | Securities Purchase Agreement | Convertible Promissory Note
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 15,000
Debt instrument maturity date		Aug. 18, 2022
Debt Instrument, annual interest rate		0.59%
Conversion price (dollars per share) | $ / shares		$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 64,500
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 31,400